TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6446691
Drug: Aminooxyacetic acid
DrugBank: Aminooxyacetic acid (DB02079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminooxyacetic acid (AOAA) at a dosage of 2 mg per kilogram per day
Study: 6408155
Drug: Nomifensine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (200 mg po)
Study: 24895878
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (n = 167)
Study: 24895878
Drug: Intravenous tissue-plasminogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue-plasminogen activator (IV tPA) (n = 23)
Study: 15838889
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (TAC + corticosteroids)
Study: 15838889
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TAC + corticosteroids + AZA)
Study: 12492189
Drug: Conventional Colonoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Colonoscope (CC)
Study: 10458221
Drug: Epirubicin 200
Normalized name: epiRUBicin 200 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 200 mg/m2 and cyclophosphamide 4 g/m2 with progenitor cell and filgrastim support every 28 days (n = 79) or 21 days (n = 20)
Study: 11014391
Drug: Morphine (MO)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (MO) plus Flumazenil (FL) (MO 2 mg + FL 0.2 mg)
Study: 11014391
Drug: Morphine (MO)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (MO) only (MO 2 mg)
Study: 8514472
Drug: Minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline hydrochloride injection after cyst aspiration
Study: 14667889
Drug: DHEA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (25 mg/d orally)
Study: 30670642
Drug: Risperidone (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (dopamine antagonist)
Study: 12644340
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (angiography only for patients with recurrent ischemia at rest or a positive stress test) with tirofiban (for 48 h) plus aspirin and heparin
Study: 9640159
Drug: 0.375% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% ropivacaine 1.0 ml kg‐1
Study: 9640159
Drug: 0.375% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% bupivacaine 1.0 ml kg‐1
Study: 30551218
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of antidepressants
Study: 23015748
Drug: Adjunctive antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antidepressant treatment
Study: 18808424
Drug: Levetiracetam therapy
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam therapy
Study: 11137250
Drug: AlPO(4)‐adjuvated vaccine/2+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AlPO(4)‐adjuvated vaccine/2+1 schedule
Study: 11137250
Drug: AlPO(4)‐adjuvated vaccine/3+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AlPO(4)‐adjuvated vaccine/3+1 schedule
Study: 11137250
Drug: Al(OH)(3)‐adjuvated vaccine/2+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al(OH)(3)‐adjuvated vaccine/2+1 schedule
Study: 9085953
Drug: Hydromorphone (HM)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HM) 0.075 mg/mL + Nalbuphine (NB) 0.02 mg/mL
Study: 9085953
Drug: Hydromorphone (HM)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HM) 0.075 mg/mL + Nalbuphine (NB) 0.08 mg/mL
Study: 9085953
Drug: Hydromorphone (HM)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HM) 0.075 mg/mL
Study: 8280544
Drug: Diamorphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 2.5 mg in saline 10 ml
Study: 8280544
Drug: Diamorphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 2.5 mg in 1:200,000 adrenaline 10 ml
Study: 31317471
Drug: 200 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg/day selenium supplements as selenium yeast
Study: 27484082
Drug: Adjunctive steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive steroid (triamcinolone acetonide) given at the time of surgery (4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml sub‐Tenon's).
Study: 27484082
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment and care (control group).
Study: 20626379
Drug: Brief detoxification
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief detoxification treatment (DETOX)
Study: 20626379
Drug: Extended buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended buprenorphine-naloxone (BUP) treatment
Study: 18058832
Drug: Galantamine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram)
Study: 18058832
Drug: Placebo augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram)
Study: 12534638
Drug: Meloxicam administered
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam administered once daily for 3 weeks or 6 months at doses between 7.5 and 60 mg
Study: 8705294
Drug: Transferrin receptor
Normalized name: Transferrin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transferrin receptor in brain tissues from AD patients
Study: 6897039
Drug: Oral molsidomine
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral molsidomine 4 mg
Study: 6510452
Drug: Sustained-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release isosorbide dinitrate (ISDN) 40 mg
Study: 22059409
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of selected lactobacilli up to the 24th to 26th week of gestation
Study: 19037804
Drug: Capsinoids (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (15 mg/person)
Study: 19037804
Drug: Capsinoids (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (30 mg/person)
Study: 19037804
Drug: Capsinoids (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (15 or 30 mg/person)
Study: 16935685
Drug: As-needed terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed terbutaline (0.4 mg)
Study: 12617263
Drug: Interferon-beta-1a (Rebif)
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta-1a (Rebif) treatment
Study: 10871468
Drug: High-dose magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose magnesium sulfate (5 g/h)
Study: 10871468
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium sulfate (2 g/h)
Study: 4007253
Drug: Adsorbed tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbed tetanus vaccine from source 1
Study: 4007253
Drug: Adsorbed tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbed tetanus vaccine from source 2
Study: 17082219
Drug: Radical prostatectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical prostatectomy plus endocrine therapy
Study: 17082219
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy plus endocrine therapy
Study: 9162292
Drug: Bemitil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemitil (0.5 g)
Study: 9235216
Drug: Phenibut (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenibut (0.25 g)
Study: 3753670
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg nifalatide
Study: 3753670
Drug: 48 mg
Normalized name: betaine 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 mg nifalatide
Study: 31915163
Drug: Adjunctive azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive azithromycin
Study: 30721208
Drug: Aflibercept administered
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept administered as 1 injection every other month after 3 initial monthly doses
Study: 27458584
Drug: Aprepitant (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (40 mg) + Dexamethasone (10 mg IV) + Promethazine (25 mg IV)
Study: 27458584
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg IV) + Dexamethasone (10 mg IV) + Promethazine (25 mg IV)
Study: 12953801
Drug: Palatinose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatinose (5 g)
Study: 28612237
Drug: L-thyroxine
Normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine
Study: 1565347
Drug: Quartered 20-mg
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quartered 20-mg PGE2 suppository
Study: 12091845
Drug: Albuterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (400 microg) nebulization, repeated every 2 hours until potassium level fell below 5 mmol/L (maximum 12 doses)
Study: 10890262
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% ophthalmic solution BID
Study: 10890262
Drug: Terfenadine 60-mg
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60-mg tablets BID
Study: 7724098
Drug: Intravaginal prostaglandin
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal prostaglandin E2 (PGE2) suppositories
Study: 7724098
Drug: Intramuscular 15-methyl-prostaglandin
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 15-methyl-prostaglandin F2 alpha (15M-PGF2 alpha)
Study: 31301621
Drug: Supported self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported self-help preventive cognitive therapy (S-PCT)
Study: 17265038
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo IV (up to 3 injections at least 5 min apart)
Study: 10518857
Drug: Type-A zeolite
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Type-A zeolite mouthrinse (placebo), rinsed twice a day for five days
Study: 8129004
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 400 mg of sparfloxacin
Study: 8129004
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily oral doses totaling 1,000 mg of sparfloxacin
Study: 22123970
Drug: Social support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support from female partner or close female friend during preparation for a stressful task
Study: 22123970
Drug: No social
Approvals — FDA: no, EMA: no, PMDA: no
Description: No social support during preparation for a stressful task
Study: 17425628
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg taken 15 min before a high-fat meal (fed)
Study: 15206668
Drug: Racemic citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic citalopram (20 mg)
Study: 10023285
Drug: Intra-articular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular ketorolac 5 mg
Study: 7485885
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 10 mg
Study: 9106379
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diphenhydramine
Study: 31618678
Drug: 6 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 days of oral flucloxacillin
Study: 31618678
Drug: Modified cure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified cure assessment for 6 days of therapy
Study: 31618678
Drug: Modified cure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified cure assessment for 12 days of therapy
Study: 30551654
Drug: L. rhamnosus
Normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. rhamnosus 19070‐2 and L. reuteri 12246 with 250 × 10⁶ CFU, 3.33 mg of fructooligosaccharide, and 200 IU of vitamin D₃ (probiotic group)
Study: 27798661
Drug: Postoperative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatments for cancer
Study: 24916558
Drug: Preworkout supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preworkout supplement (SUP) containing caffeine, creatine, β-alanine, amino acids, and B vitamins, ingested daily for 28 days.
Study: 24916558
Drug: Preworkout supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preworkout supplement (SUP)
Study: 23149797
Drug: Continuously variable
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuously variable dose rate (CVDR)
Study: 20855397
Drug: Day care
Normalized name: CVS Everyday Care Probiotic Vegetable Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day care management with antibiotic treatment, feeding, and supportive care from 8:00 am to 5:00 pm.
Study: 20855397
Drug: Hospital care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital care management with similar 24-hour treatment.
Study: 12870164
Drug: High-dose Caiapo
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Caiapo (4 g/d)
Study: 12870164
Drug: Low-dose Caiapo
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Caiapo (2 g/d)
Study: 9109825
Drug: Two-solution rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-solution rinse
Study: 25977313
Drug: Fenoldopam (D1-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (D1-like receptor agonist) during low NaCl diet
Study: 25977313
Drug: Fenoldopam with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam with enalapril (ACE inhibitor) during low NaCl diet
Study: 18795988
Drug: 25 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/wk testosterone enanthate
Study: 18795988
Drug: 50 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/wk testosterone enanthate
Study: 18795988
Drug: 125 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/wk testosterone enanthate
Study: 18795988
Drug: 300 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/wk testosterone enanthate
Study: 16374438
Drug: Antibiotic lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic lock solution (cefazolin 10 mg/ml, gentamicin 5 mg/ml, heparin 1000 U/ml)
Study: 16374438
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock solution (heparin 1000 U/ml)
Study: 16374438
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock solution
Study: 16374438
Drug: Antibiotic lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic lock solution
Study: 12749507
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg orally once daily
Study: 12749507
Drug: Fenofibrate 67
Normalized name: fenofibrate 67 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 67 mg orally TID
Study: 24139613
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy
Study: 27028913
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (Vivitrol) for 24 weeks
Study: 24953333
Drug: Gefitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib monotherapy (250 mg/day)
Study: 15499696
Drug: Gefitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib monotherapy
Study: 22762856
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (571-mg metformin acetate)
Study: 22762856
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (500-mg metformin hydrochloride)
Study: 11061280
Drug: Prednisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (20 mg daily for 4 weeks, then 10 mg daily for 1 year, followed by gradual withdrawal over 16 weeks)
Study: 9314342
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite avoidance treatment (Acarosan applied to floors, impermeable covers for mattresses and bedding)
Study: 29745073
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of colloid (10mg/kg) and crystalloid solutions
Study: 29745073
Drug: Crystalloid solutions
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid solutions only
Study: 27917214
Drug: Treadmill walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill walking exercise training for six months in addition to medical treatment
Study: 18671874
Drug: Intermittent Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Preventive Treatment in infants (IPTi)
Study: 3852899
Drug: Sulbenicillin (SBPC)
Normalized name: sulbenicillin
DrugBank: Sulbenicillin (DB13693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbenicillin (SBPC) 2 g administered intravenously twice a day for 7 days
Study: 29097028
Drug: actoxumab 10
Normalized name: Actoxumab
DrugBank: Actoxumab (DB16376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: actoxumab 10 mg/kg + bezlotoxumab 10 mg/kg
Study: 18162446
Drug: Levocetirizine (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (5mg oral administration)
Study: 14518696
Drug: Enfuvirtide (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (45 mg, 67.5 mg, or 90 mg twice daily) with background ARV regimen
Study: 14518696
Drug: Enfuvirtide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (all doses)
Study: 10996576
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin nasal spray 100 IU
Study: 10996576
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin nasal spray 400 IU
Study: 10996576
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin nasal spray (all active treatment groups)
Study: 9165960
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg.kg‐1
Study: 1672803
Drug: vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.1 mg.kg‐1
Study: 3541420
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg isosorbide‐5‐mononitrate
Study: 3541420
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg isosorbide‐5‐mononitrate
Study: 3541420
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg isosorbide‐5‐mononitrate
Study: 9046389
Drug: 0.25 g
Normalized name: AMICAR 0.25 GM/mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g of ethanol/kg of body weight
Study: 9046389
Drug: 0.50 g
Normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 g of ethanol/kg of body weight
Study: 8803645
Drug: Intravenous flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flumazenil
Study: 24105303
Drug: Hypothermia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia group (loading dose of 4°C cold saline, cooled to 32°C to 34°C for 48 hours)
Study: 21176107
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) using reticulated open‐cell foam (ROCF)
Study: 12697591
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (thiopental 5 mg kg(‐1), fentanyl 3 micro g kg(‐1), vecuronium 0.08 mg kg(‐1))
Study: 19152909
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (fluid restriction then nothing by mouth 12 hours before the procedure, water and simethicone at capsule ingestion)
Study: 19152909
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation + 10 mg oral metoclopramide before the procedure
Study: 19152909
Drug: Citramag +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citramag + senna + 10 mg metoclopramide before the procedure
Study: 15891596
Drug: Prokinetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic therapy with cisapride (10 mg t.i.d.) after 4 weeks
Study: 3292844
Drug: Intra-vaginal suppositories
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-vaginal suppositories containing S. nigrescens maceration
Study: 3292844
Drug: Nystatin suppositories
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin suppositories
Study: 29995693
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise (CEX) including 2 aerobic and 9 resistance exercises performed alternately in circuit order for 40 minutes at 60-70% heart rate reserve using body mass or fixed loads.
Study: 26189007
Drug: Imatinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 200 mg single dose
Study: 18608522
Drug: Diane35 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane35 (35 microg ethinyl estradiol plus 2 mg cyproterone acetate)
Study: 18608522
Drug: Diane35 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane35 and Diane35/metformin
Study: 12460869
Drug: urapidil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil (10 mg IC)